NHWA(SZ:002262)2023-03-20 16:00Financial Performance - The company's operating revenue for 2022 was ¥4,298,513,062.14, representing a year-on-year increase of 9.22% from ¥3,935,664,219.52 in 2021[13]. - The net profit attributable to shareholders for 2022 was ¥900,926,029.55, which is a 12.93% increase compared to ¥797,777,327.57 in 2021[13]. - The basic earnings per share for 2022 was ¥0.89, up 12.66% from ¥0.79 in 2021[13]. - The total assets at the end of 2022 amounted to ¥6,481,745,574.76, reflecting a 13.77% increase from ¥5,697,186,706.05 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥5,622,248,624.37, which is a 14.26% increase from ¥4,920,688,031.43 at the end of 2021[13]. - In Q4 2022, the operating revenue reached ¥1,178,387,350.86, with a net profit attributable to shareholders of ¥159,051,214.46[16]. - The company reported a cash flow from operating activities of ¥861,023,149.69 for the year 2022, which is a 22.81% increase from ¥701,117,596.67 in 2021[13]. - The company recognized government subsidies amounting to ¥46,912,734.05 in 2022, compared to ¥32,743,590.42 in 2021[17]. - The weighted average return on equity for 2022 was 17.20%, slightly down from 17.69% in 2021[13]. - The company reported a total of ¥28,166,708.35 in non-recurring gains and losses for 2022[17]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares to all shareholders, based on a total of 1,007,588,092 shares[2]. - The proposed cash dividend for 2022 is ¥2.00 per 10 shares, totaling ¥201,517,618.40, with no stock dividends or capital reserve transfers[133]. - The cumulative cash dividend amount from 2019 to 2021 was approximately ¥604.19 million, accounting for 82.77% of the average annual net profit during the same period[153]. - After the dividend distribution, the retained undistributed profit will be ¥3,776,835,195.20, to be carried forward for future distribution[133]. Market and Industry Trends - The pharmaceutical industry in China is experiencing significant growth, with healthcare expenditure as a percentage of GDP reaching 4.83% in 2022, indicating a rising demand for medical services[21]. - Chronic disease prevalence in China has reached 23%, with chronic diseases accounting for 86% of total deaths, leading to increased long-term medication and healthcare costs[21]. - The central nervous system (CNS) drug market in China is still in its early stages, with only 3% of the global CNS drug consumption, compared to 49% in the US and 26% in Europe[23]. - The aging population and rising health awareness among the public are expected to drive further growth in the pharmaceutical sector, presenting significant opportunities for companies like Jiangsu Enhua[22]. - The ongoing healthcare reforms and policies, such as centralized procurement, are pushing pharmaceutical companies to innovate and improve their R&D capabilities[21]. Research and Development - The company has a robust product pipeline with 22 innovative drug projects and 38 generic drug projects currently under development, alongside 15 projects undergoing consistency evaluation[23]. - The company increased R&D investment to CNY 495,383,504.42, a growth of 23.10% compared to the previous year, with over 70 ongoing research projects[30]. - There are currently 22 innovative drug projects under development, including 1 in Phase II clinical trials and 4 in Phase I clinical trials, with 5 projects expected to submit clinical applications in 2023[30]. - The company has launched 38 generic drug projects, with 2 generic drug production approvals obtained during the reporting period[30]. - The company has applied for 127 invention patents and received 44 authorized invention patents during the reporting period[30]. Corporate Governance - The company reported a commitment to improving corporate governance, aligning with regulations from the China Securities Regulatory Commission and the Shenzhen Stock Exchange, enhancing internal control systems[97]. - The board of directors consists of four independent directors, exceeding one-third of the total board members, ensuring compliance with governance standards[98]. - The company has established a mechanism to prevent major shareholders from occupying company funds, safeguarding the interests of minority shareholders[97]. - The company emphasizes transparent communication with investors, implementing various channels for interaction, including online platforms and direct communication[99]. - The company has a comprehensive human resources management system that includes detailed regulations on recruitment, training, compensation, and performance evaluation[154]. Environmental Responsibility - The company strictly adheres to environmental protection laws and regulations, ensuring wastewater and air emissions meet national standards[143]. - The company invested approximately CNY 15.22 million in environmental governance and protection, including the purchase of environmental protection equipment and facility upgrades[151]. - The company implemented a wastewater treatment system with a capacity of 800 tons per day at the Jinshanqiao plant, ensuring that treated wastewater meets discharge standards[146]. - The company achieved over 95% efficiency in VOC treatment after upgrading its exhaust gas treatment systems, with an investment of CNY 3 million in 2022[147]. - The company has not faced any administrative penalties related to environmental issues in 2022[152]. Social Responsibility - The company actively participates in charitable activities, contributing medicines and funds to local poverty alleviation efforts, enhancing its social responsibility image[99]. - The company has established the "Enhua Caring Fund," which has donated a total of 807,800 yuan to assist socially disadvantaged families over the past seven years[159]. - The company collaborates with Nanjing Medical University to provide 60,000 yuan in scholarships annually to outstanding students in the field of psychiatry[159]. - The company has committed 480,000 yuan to support rural revitalization efforts, directly benefiting local communities[160]. - The company has been fulfilling its social responsibilities by supporting education, culture, science, and health initiatives in local areas[159]. Future Outlook - The company aims for approximately 15% growth in business revenue, total profit, and net profit in 2023 compared to the audited data of 2022[86]. - The company plans to advance 6 innovative drug clinical trials in 2023 and aims to establish 3-5 new innovative drug projects, with a goal of submitting 5 innovative drug applications for clinical trials[86]. - The company is focusing on high-barrier generic drugs and has 4 projects undergoing consistency evaluation, with 3 expected to be approved in 2023[87]. - The company is enhancing its marketing strategies to strengthen new product market access and aims to maintain its leading position in the central nervous system drug sector[88]. - The company is committed to optimizing production management and cost control, with a focus on improving product quality and reducing complaints[87].